172 related articles for article (PubMed ID: 22876296)
1. Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model.
Ramsberg J; Asseburg C; Henriksson M
PLoS One; 2012; 7(8):e42003. PubMed ID: 22876296
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium.
Annemans L; Brignone M; Druais S; De Pauw A; Gauthier A; Demyttenaere K
Pharmacoeconomics; 2014 May; 32(5):479-93. PubMed ID: 24554474
[TBL] [Abstract][Full Text] [Related]
3. Network Meta-Analysis and Cost-Effectiveness Analysis of New Generation Antidepressants.
Khoo AL; Zhou HJ; Teng M; Lin L; Zhao YJ; Soh LB; Mok YM; Lim BP; Gwee KP
CNS Drugs; 2015 Aug; 29(8):695-712. PubMed ID: 26293743
[TBL] [Abstract][Full Text] [Related]
4. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
5. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
[TBL] [Abstract][Full Text] [Related]
6. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Wade AG; Toumi I; Hemels ME
Curr Med Res Opin; 2005 Apr; 21(4):631-42. PubMed ID: 15899113
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Geddes JR; Higgins JP; Churchill R; Watanabe N; Nakagawa A; Omori IM; McGuire H; Tansella M; Barbui C
Lancet; 2009 Feb; 373(9665):746-58. PubMed ID: 19185342
[TBL] [Abstract][Full Text] [Related]
10. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
11. A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder.
Armstrong EP; Malone DC; Erder MH
Curr Med Res Opin; 2008 Apr; 24(4):1115-21. PubMed ID: 18331669
[TBL] [Abstract][Full Text] [Related]
12. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder.
Armstrong EP; Skrepnek GH; Haim Erder M
Curr Med Res Opin; 2007 Feb; 23(2):251-8. PubMed ID: 17288678
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.
Cipriani A; Furukawa TA; Salanti G; Chaimani A; Atkinson LZ; Ogawa Y; Leucht S; Ruhe HG; Turner EH; Higgins JPT; Egger M; Takeshima N; Hayasaka Y; Imai H; Shinohara K; Tajika A; Ioannidis JPA; Geddes JR
Lancet; 2018 Apr; 391(10128):1357-1366. PubMed ID: 29477251
[TBL] [Abstract][Full Text] [Related]
14. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
Lenox-Smith A; Conway P; Knight C
Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of mirtazapine versus paroxetine in treating people with depression in primary care.
Romeo R; Patel A; Knapp M; Thomas C
Int Clin Psychopharmacol; 2004 May; 19(3):125-34. PubMed ID: 15107654
[TBL] [Abstract][Full Text] [Related]
16. Modelling the cost effectiveness of antidepressant treatment in primary care.
Revicki DA; Brown RE; Palmer W; Bakish D; Rosser WW; Anton SF; Feeny D
Pharmacoeconomics; 1995 Dec; 8(6):524-40. PubMed ID: 10160081
[TBL] [Abstract][Full Text] [Related]
17. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
Favré P
Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings.
Revicki DA; Brown RE; Keller MB; Gonzales J; Culpepper L; Hales RE
J Clin Psychiatry; 1997 Feb; 58(2):47-58. PubMed ID: 9062373
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics of antidepressants in moderate-to-severe depressive disorder in Colombia.
Machado M; Lopera MM; Diaz-Rojas J; Jaramillo LE; Einarson TR;
Rev Panam Salud Publica; 2008 Oct; 24(4):233-9. PubMed ID: 19133171
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine versus other anti-depressive agents for depression.
Cipriani A; Koesters M; Furukawa TA; Nosè M; Purgato M; Omori IM; Trespidi C; Barbui C
Cochrane Database Syst Rev; 2012 Oct; 10():CD006533. PubMed ID: 23076926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
